This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Albert Segaloff, MD

JAMA. 1975;234(11):1175-1177.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WHEN patients can be identified as having clinically recurrent and progressive breast cancer, our first choice of therapy generally should be hormonal in nature. Certain patients, ie, those whose only clinical metastatic disease involves the brain, should be treated primarily with whole-brain radiation therapy under the protection of high-dose corticosteroid administration, while patients with rapidly advancing and extensive pulmonary disease may be better candidates for multiple chemotherapeutic regimens that include corticosteroids as initial therapy.

Although we hope that the determination of cytoplasmic estrogen receptors may be of assistance in recognizing hormonally responsive patients, neither the state of the art nor the availability of facilities is such at present that we can recommend this as a method for choosing hormonal therapy for patients. It appears, however, that the absence of cytoplasmic estrogen receptors in breast cancer may help to reject patients for hormonal manipulation.¹

Premenopausal Women

It is generally agreed . . . [Full Text PDF of this Article]

Author Affiliations
From the Alton Ochsner Medical Foundation, New Orleans.

Footnotes
Reprint requests to Alton Ochsner Medical Foundation, 1520 Jefferson Hwy, New Orleans, LA 70121 (Dr Segaloff).

Coordinated by William H. Crosby, MD; Emil J. Freireich, MD; and Peter V. Sacks, MD.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?